Our Take
Employers are rationing GLP-1 coverage not because the drugs don't work, but because the cost math is broken and they haven't decided who pays.
Why it matters
GLP-1 drugs like Ozempic and Wegovy cost $10k+ annually per employee. HR leaders face a hard choice: fund these medications or preserve mental health programs. The trade-off signals where corporations see the ROI problem sharpest.
Do this week
Benefits leaders: audit your 2025 pharmacy budget for GLP-1 claims volume and model the per-employee cost before Q4 renewal negotiations so you can present board-ready scenarios now, not January.
Employers hit a cost ceiling on weight-loss drugs
SHRM members report struggling to fund GLP-1 medications within their current benefits budgets, according to the organization's latest annual employee benefits survey presented at SHRM26 (per HR Dive reporting). At the same time, the survey found employers increasing investment in menopause-related and pet-related benefits.
The findings point to a collision between demand for GLP-1 coverage and the hard constraints of health plan economics. These drugs, prescribed for weight loss and diabetes management, carry list prices in the $10,000 to $15,000 annual range. When a cohort of employees starts using them, the aggregate cost can blow through budget lines designed for traditional pharmacy spend.
The pullback on mental health benefits suggests prioritization is shifting, not that mental health programs are being eliminated wholesale. But the directional move is clear: something is being squeezed to make room for something else, and mental health is losing ground.
The real problem is structural, not temporary
This is not a supply problem or a "we need to wait for prices to drop" problem. Employers are rationing access because they have not solved the question of cost allocation. Specifically: who bears the risk when a new drug class drives aggregate spend 8 to 12 percent higher in a single year?
GLP-1 utilization is climbing. Payer data shows uptake accelerating across commercial plans. Unlike many high-cost drugs that affect a narrow population, GLP-1 medications apply to a much larger eligible group (anyone with obesity or prediabetes). Scale matters. One employee taking Ozempic is manageable. Thirty employees over two years is a budget crisis.
The trade-off against mental health funding is particularly sharp because mental health benefits are already fragile in many corporate plans and already underfunded relative to clinical need. Moving money from mental health to GLP-1 signals that employers see the latter as more defensible to employees ("we're helping you lose weight") even if the former is clinically more urgent.
Three things to do before year-end
1. Model your GLP-1 exposure. Pull claims data from your pharmacy vendor. How many employees are on GLP-1 therapy today? What is the average cost per user? What is the trend month-over-month? Extrapolate to 2025. This number is your planning baseline.
2. Document your mental health baseline. Before you cut mental health benefits to offset GLP-1 costs, measure what you have: utilization rates, member satisfaction, clinical outcomes if available, and out-of-pocket costs for employees. You will need this data to justify cuts to your CFO and to defend the decision to employees.
3. Explore tiering and limits now. Some plans are capping GLP-1 coverage per year, requiring prior authorization, or tiering these drugs with higher copays. If you need to ration, decide your approach (annual cap, authorization gates, copay escalation) and communicate it early. Surprise coverage denials in January create legal and morale risk.